ArticleFrontiers in medicine2021

Cost-Effectiveness Analysis of Abemaciclib Plus Fulvestrant in the Second-Line Treatment of Women With HR+/HER2- Advanced or Metastatic Breast Cancer: A US Payer Perspective.

Yingcheng Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.